[1]于筱斋?高艳香?郭紫玉?陈西霞?叶子翔?郑金刚.非阻塞性冠状动脉疾病的冠状动脉微循环功能障碍治疗新进展[J].心血管病学进展,2022,(5):385-388.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]
　YU Xiaozhai,GAO Yanxiang,GUO Ziyu,et al.Treatment of Coronary Microvascular Dysfunction in Non-Obstructive Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2022,(5):385-388.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.001]
点击复制

非阻塞性冠状动脉疾病的冠状动脉微循环功能障碍治疗新进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年5期
页码:
385-388
栏目:
出版日期:
2022-05-25

文章信息/Info

Title:
Treatment of Coronary Microvascular Dysfunction in Non-Obstructive Coronary Artery Disease
作者:
于筱斋1; 2?高艳香2?郭紫玉3?陈西霞3?叶子翔3?郑金刚1; 2
(1.中国医学科学院 北京协和医学院研究生院 中日友好临床医学院,北京 100029;2.中日友好医院 心脏科,北京 100029;3.北京大学医学部 中日友好临床医学院,北京 100029)
Author(s):
YU Xiaozhai1; 2; GAO Yanxiang2; GUO Ziyu3; CHEN Xixia3; YE Zixiang3; ZHENG Jingang1; 2
（1.Graduate School of Chinese Academy of Medical Sciences & Peking Union Medical College, China-Japan Friendship School of Clinical Medicine,Beijing 100029,China; 2. Department of Cardiology,China-Japan Friendship Hospital,Beijing 100029,China; 3. Peking University China-Japan Friendship School of Clinical Medicine,Beijing 100029,China)
关键词:
非阻塞性冠状动脉疾病; 冠状动脉微循环功能障碍; 药物治疗
Keywords:
Non-obstructive coronary artery disease; Coronary microvascular dysfunction; Drug treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2022.05.001
摘要:
冠状动脉微循环功能障碍（CMVD）是指冠状动脉微血管结构和/或功能异常，导致冠状动脉血流量及心肌灌注量减少，增加心血管事件风险，严重影响患者的生存率和预后。在中国，CMVD治疗多为经验性的，有6.3%的冠状动脉微循环病变患者获得正确治疗。近年，非阻塞性冠状动脉疾病的CMVD研究增多，发现一些药物对其具有潜在的治疗意义，现就非阻塞性冠状动脉疾病的CMVD治疗进展做一综述。
Abstract:
Coronary microvascular dysfunction(CMVD) refers to the abnormal structure and/or function of coronary microvessels,which leads to the decrease of coronary blood flow and myocardial perfusion,increases the risk of cardiovascular events,and seriously affects the survival rate and prognosis of patients. In China,the treatment of CMVD is mostly empirical,and 6.3% of patients with coronary microcirculation lesions receive correct treatment. In recent years,the research on CMVD of non-obstructive coronary artery disease has increased,and some drugs have potential therapeutic significance. This paper reviews the progress of CMVD treatment of non-obstructive coronary artery disease.

参考文献/References:

[1] Taqueti VR,di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options:JACC state-of-the-art review[J]. J Am Coll Cardiol,2018,72(21):2625-2641.

[2] Rush CJ,Berry C,Oldroyd KG,et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction[J]. JAMA Cardiol,2021,6(10):1130-1143.

[3] AlBadri A,Bairey Merz CN,Johnson BD,et al. Impact of abnormal coronary reactivity on long-term clinical outcomes in women[J]. J Am Coll Cardiol,2019,73(6):684-693.

[4] Bairey Merz CN,Pepine CJ,Shimokawa H,et al. Treatment of coronary microvascular dysfunction[J]. Cardiovasc Res,2020,116(4):856-870.

[5] Kotseva K,de Backer G,de Bacquer D,et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries:results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry[J]. Eur J Prev Cardiol,2019,26(8):824-835.

[6] Ahmad A,Corban MT,Toya T,et al. Coronary microvascular endothelial dysfunction in patients with angina and nonobstructive coronary artery disease is associated with elevated serum homocysteine levels[J]. J Am Heart Assoc,2020,9(19):e017746.

[7] Khuddus MA,Pepine CJ,Handberg EM,et al. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease:a substudy from the National Heart,Lung and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation(WISE)[J]. J Interv Cardiol,2010,23(6):511-519.

[8] Chiang CY,Chien CY,Qiou WY,et al. Genetic depletion of thromboxane A2/thromboxane-prostanoid receptor signalling prevents microvascular dysfunction in ischaemia/reperfusion injury[J]. Thromb Haemost,2018,118(11):1982-1996.

[9] Task Force Members,Montalescot G,Sechtem U,et al. 2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J,2013,34(38):2949-3003.

[10] Caliskan M,Erdogan D,Gullu H,et al. Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow[J]. Clin Cardiol,2007,30(9):475-479.

[11] Zhang X,Li Q,Zhao J,et al. Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X[J]. Coron Artery Dis,2014,25(1):40-44.

[12] Galderisi M,D’Errico A,Sidiropulos M,et al. Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension[J]. J Hypertens,2009,27(10):2108-2115.

[13] Sütsch G,O echslin E,M ayer I,et al. Effect of diltiazem on coronary flow reserve in patients with microvascular angina[J]. Int J Cardiol,1995,52(2):135- 143.

[14] Russo G,di Franco A,Lamendola P,et al. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina[J]. Cardiovasc Drugs Ther,2013,27(3):229-234.

[15] Wu M,V illano A,R usso G,et al. Poor tolerance and limited effects of isosorbide-5-mononitrate in microvascular angina[J]. Cardiology,2015,130(4):201- 206.

[16] Motz W,S trauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril[J]. Hypertension,1996,27(5):1031- 1038.

[17] Pauly DF,J ohnson BD,A nderson RD,et al. In women with symptoms of cardiac ischemia,nonobstructive coronary arteries,and microvascular dysfunction,angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart,Lung and Blood Institute Women’s Ischemia Syndrome Evaluation(WISE)[J]. Am Heart J,2011,162(4):678- 684.

[18] Jiang X,W u D,J iang Z,et al. Protective effect of nicorandil on cardiac microvascular injury:role of mitochondrial integrity[J]. Oxid Med Cell Longev,2021,2021:4665632.

[19] Chen JW,L ee WL,H su NW,et al. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina[J]. Am J Cardiol,1997,80(1):32- 38.

[20] Ahmed B,Mondragon J,Sheldon M,et al. Impact of ranolazine on coronary microvascular dysfunction(MICRO) study[J]. Cardiovasc Revasc Med,2017,18(6):431-435.

[21] Bairey Merz CN,Handberg EM,Shufelt CL,et al. A randomized,placebo-controlled trial of late Na current inhibition(ranolazine) in coronary microvascular dysfunction(CMD):impact on angina and myocardial perfusion reserve[J]. Eur Heart J,2016,37(19):1504-1513.

[22] Rambarat CA,Elgendy IY,Handberg EM,et al. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction:Women’s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study[J]. Int J Cardiol,2019,276:8-13.

[23] Villano A,di Franco A,Nerla R,et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris[J]. Am J Cardiol,2013,112(1):8-13.

[24] Tagliamonte E,Cirillo T,Rigo F,et al. Ivabradine and bisoprolol on Doppler-derived coronary flow velocity reserve in patients with stable c oronary artery disease:beyond the heart rate[J]. Adv Ther,2015,32(8):757-767.

[25] Vaduganathan M,Claggett BL,Jhund PS,et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction:a comparative analysis of three randomised controlled trials[J]. Lancet,2020,396(10244):121-128.

[26] Anker SD,Butler J,Filippatos G,et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med,2021,385(16):1451-1461.

[27] Adingupu DD,G?pel SO,Gr?nros J,et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice[J]. Cardiovasc Diabetol,2019,18(1):16.

[28] Zinman B,Wanner C,Lachin JM,et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.

[29] Reriani M,Raichlin E,Prasad A,et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis[J]. Circulation,2010,122(10):958-966.

[30] Ford TJ,Corcoran D,Padmanabhan S,et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction[J]. Eur Heart J,2020,41(34):3239-3252.

[31] Denardo SJ,Wen X,Handberg EM,et al. Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women:a Women’s Ischemia Syndrome Evaluation(WISE) ancillary study[J]. Clin Cardiol,2011,34(8):483-487.

[32] Mohri M,Shimokawa H,Hirakawa Y,et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm[J]. J Am Coll Cardiol,2003,41(1):15-19.

相似文献/References:

[1]谢乃容 赵薇 秦明照.缺血伴非阻塞性冠状动脉疾病研究进展[J].心血管病学进展,2019,(8):1134.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]
　XIE NairongZHAO WeiQIN Mingzhao.Ischemia with No Obstructive Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2019,(5):1134.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.017]
[2]杨嘉馨 丁耀东 葛海龙.冠状动脉微循环功能的检测与评估[J].心血管病学进展,2021,(3):207.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.004]
　YANG Jiaxin,DING Yaodong,GE Hailong.Detection and Assessment of Coronary Microcirculation Function[J].Advances in Cardiovascular Diseases,2021,(5):207.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.004]
[3]段首鹏 江洪 余锂镭.冠状动脉微循环功能障碍与自主神经研究进展[J].心血管病学进展,2022,(6):495.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.005]
　DUAN Shoupeng,JIANG Hong,YU Lilei.Coronary Microcirculation Dysfunction and Autonomic Nervous System[J].Advances in Cardiovascular Diseases,2022,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.005]

更新日期/Last Update: 2022-06-30